trending Market Intelligence /marketintelligence/en/news-insights/trending/0bv54qon31o53kkysI-E7g2 content esgSubNav
In This List

Proteostasis Therapeutics closes $42.9M common stock offering

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Insight Weekly: Labor market struggles; solar demand remains strong; banks' deposit holdings


Proteostasis Therapeutics closes $42.9M common stock offering

Proteostasis Therapeutics Inc. closed its underwritten public offering of 9.2 million common shares priced at $5 apiece for net proceeds of about $42.9 million.

The shares sold included 1.2 million shares issued pursuant to the full exercise of the underwriters' option to buy additional shares.

Proteostasis plans to use the net proceeds to advance its double and triple combination therapies in dose-range-finding and proof-of-concept studies, to advance each of its double and triple combination therapies in phase 1 clinical trials in cystic fibrosis patients and for working capital and other general corporate purposes.

Leerink Partners LLC and RBC Capital Markets LLC acted as joint book-running managers and H.C. Wainwright & Co. LLC acted as lead manager for the offering.